A Case of Management of a Patient with Long-Term Persistence of Post-COVID Syndrome and the Presence of Severe Interstitial
Changes in the Lungs
This article describes a clinical case of observation and treatment of a patient after a severe form of a new coronavirus infection. The condition was accompanied by a long symptomatic period (post-COVID period), a decrease in a number of objective criteria, and gross structural disorders detected by tomography. The logic of choice and the experience of using various drugs and their combinations for the treatment of a post-COVID state are described. Of particular interest and relevance is the observation of the use of a number of agents with potential and proven antifibrotic properties. Changes in the dynamics of computed tomography data are presented and discussed. Such situations cause significant difficulties in the work of specialists related to the rehabilitation of post-COVID patients. To date, the tactics of their treatment does not have a single approach. The description of this case can be useful in the work of general practitioners, pulmonologists, etc.
Bontsevich R.A., Zaeva A.A., Gavrilov P.V. 2023. A Case of Management of a Patient with Long-Term Persistence of Post-COVID Syndrome and the Presence of Severe Interstitial Changes in the Lungs. Challenges in Modern Medicine. 46 (1): 23–37 (in Russian). DOI: 10.52575/2687-0940-2023-46-1-23-37
While nobody left any comments to this publication.
You can be first.
Avdeev S.N. 2017. Novy`e vozmozhnosti terapii idiopaticheskogo legochnogo fibroza [New abilities in therapy of idiopathic pulmonary fibrosis]. Pul`monologiya. 27 (4): 502–514. doi: 10.18093 / 086901892017274502514
Belocerkovskaya Yu.G., Romanovskix A.G., Smirnov I.P., Sinopal`nikov A.I. 2021. Dolgij COVID-19 [AI. Long COVID-19]. Consilium Medicum. 23 (3): 261–268. doi: 10.26442/20751753.2021.3.200805
Bolevich C.B., Bolevich S.S. 2020. Kompleksny`j mexanizm razvitiya SOVID-19 [Complex mechanism of COVID-19 development]. Sechenovskij vestnik. 11 (2): 50–61. doi: 10.47093/2218-7332.2020.11.2.50-61
Boncevich R.A., Vovk Ya.R., Adonina A.V., Solov`yova L.V. 2020. Opy`t vedeniya pacienta s oslozhnenny`m techeniem SARS-CoV-2 infekcii: rannyaya legochnaya reabilitaciya iprofilaktika pnevmofibroza (klinicheskij sluchaj) [Experience in managing a patient with a complicated course of SARS-CoV-2 infection: early pulmonary rehabilitation and prevention of pulmonary fibrosis (clinical case)]. Aktual`ny`e problemy` mediciny`. 43 (3): 365–372. doi: 10.18413/2687-0940-2020-43-3-365-372
Vremenny`e metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19) [Ministry of Health of Russia. Temporary guidelines «Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)]». Versiya 16 (18.08.2022).
Gajnitdinova V.V., Avdeev S.N., Merzhoeva Z.M., Berikxanov Z.G., Medvedeva I.V., Gorbacheva T.L. 2021. Opy`t primeneniya N-acetilcisteina v kompleksnom lechenii srednetyazheloj COVID-associirovannoj pnevmonii [N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia]. Pul`monologiya. 31 (1): 21–29. doi: 10.18093/0869-0189-2021-31-1-21-29
Efremova O.A., Kamy`shnikova L.A., Shelyakina E.V., Shkilyova I.Yu., Xodosh E`.M., Efimenko E.V. 2016. Rol` xronicheskoj obstruktivnoj bolezni lyogkix v razvitii polimorbidnoj patologii [The role of chronic obstructive pulmonary disease in the development of polymorbid pathology. scientific result]. Nauchny`j rezul`tat. Medicina i farmaciya. 2(4): 13–18. doi: 10.18413/2313-8955-2016-2-4-13-18
Zhestkov A.V., Xamitov R.F., Vizel` A.A., Zolotov M.O. 2022. Fibrozny`e porazheniya legochnoj tkani: vozmozhnosti lecheniya pacientov, perenesshix COVID-19 [Fibrous lung tissue lesions: treatment opportunities for post-COVID-19 patients]. Nauka i innovacii v medicine.7 (2): 81–84. doi: 10.35693/2500-1388-2022-7-2-81-84
Zajcev A.A., Leshhenko I.V. 2022. Prodolzhayushhijsya simptomaticheskij COVID-19 – prakticheskie rekomendacii [Ongoing symptomatic COVID-19 – practical advice: A review]. Consilium Medicum. 24 (3): 209–212. doi: 10.26442/20751753.2022.3.201531
Zajcev A.A., Ternovskaya N.A., Chelan E.A., Kulagina, Sidorov Yu.A., Lixodij V.I. 2022. Prodolzhayushhijsya simptomaticheskij COVID-19 – vozmozhnosti farmakoterapii [Ongoing symptomatic COVID-19 – pharmacotherapy possibilities]. Vestnik sovremennoj klinicheskoj mediciny`. 15 (1): 26–33. doi: 10.20969/VSKM.2022.15(1).26-33
Kotova N.V., Polyanskij A.V. 2021. Chto delat` s pacientom, perenesshim COVID-pnevmoniyu? Opy`t klinicheskogo ispol`zovaniya Bovgialuronidazy` Azoksimer (Longidazy`) dlya profilaktiki i lecheniya post-kovidnogo pnevmofibroza lyogkix [What to do with a patient who has had COVID-pneumonia? Experience in the clinical use of Bovhyaluronidase Azoxymer (Longidase) for the prevention and treatment of post-COVID pulmonary fibrosis]. Glavny`j vrach YuGA Rossii. 4 (79): 11–12.
Kuzubova N.A., Titova O.N., Lebedeva E.S., Volchkova E.V. 2021. Legochny`j fibroz, associirovanny`j s COVID-19 [Pulmonary fibrosis associated with COVID-19]. RMZh. Medicinskoe obozrenie. 5 (7): 492–496. doi: 10.32364/2587-6821-2021-5-7-492-496.
Osnovy` immunoreabilitacii pri novoj koronavirusnoj infekcii (COVID-19) [Fundamentals of immunorehabilitation for a new coronavirus infection (COVID-19)]. Posobie dlya vrachej. 2020. Pod. red. M.P. Kostinova. - M.: Gruppa MDV. 112 s.
Safronenko V.A., Gasanov M.Z. 2015. Fizioterapiya i fizioprofilaktika [Physiotherapy and physioprophylaxis]. Ucheb.-metod. posobie GBOU VPO RostGMU Minzdrava Rossii, kaf. vnutrennix boleznej s osnovami obshhej fizioterapii № 1 - Rostov na Donu: Izd-vo RostGMU. 107 s.
Franczuzevich L.Ya., Bobkov A.P., Petryajkin F.A., Kravchenko N.Yu., Krasnova T.N., Belevskij A.S. 2021. Perspektivy` primeneniya N-acetilcisteina u pacientov s dlitel`ny`mi respiratorny`mi simptomami post-COVID-19: danny`e nauchnoj literatury` i sobstvenny`j klinicheskij opy`t [Prospects for the use of N-acetylcysteine in patients with prolonged post-COVID-19 respiratory symptoms: evidence from the scientific literature and own clinical experience]. Prakticheskaya pul`monologiya. 2: 42–52. doi: 10.24412/2409-6636-2021-12690
Hodosh E`.M., Ivaxno I.V., Efremova O.A., Obolonkova N.I., Golivecz T.P., Xamnagadaev I.I. 2022. Klinicheskie i patomorfologicheskie patterny` diffuznogo al`veolyarnogo porazheniya, obuslovlennogo COVID-19, u pacientov, nuzhdayushhixsya v respiratornoj podderzhke [Clinical and pathological patterns of diffuse alveolar damage due to COVID-19 in patients requiring respiratory support]. Aktual`ny`e problemy` mediciny`. 45 (1): 39–54. doi: 10.52575/2687-0940-2022-45-1-39-54
Bazdyrev E., Rusina P., Panova M., Novikov F., Grishagin I., Nebolsin V. 2021. Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel). 14 (8): 807. doi: 10.3390/ph14080807
Bontsevich R., Vovk Y., Solovyova L. 2021. COVID-19: treatment of early chronic COVID syndrome. European Respiratory Journal Sep, 58 (suppl 65) PA3674. doi: 10.1183/13993003.congress-2021.PA3674
Delpino M.V., Quarleri J. 2020. SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Front Cell. Infect. Microbiol. 10: 340. doi: 10.3389/fcimb.2020.00340
Desai A.D., Lavelle M., Boursiquot B.C., Wan E.Y. 2022. Long-term complications of COVID-19. Am. J. Physiol. Cell. Physiol. 322 (1): C1-C11. doi: 10.1152/ajpcell.00375.2021
George P.M., Wells A.U., Jenkins R.G. 2020. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet. Respir. Med. 8 (8): 807–815. doi: 10.1016/S2213-2600(20)30225-3
Lechowicz K., Drożdżal S., Machaj F., Rosik J., Szostak B., Zegan-Barańska M., Biernawska J., Dabrowski W., Rotter I., Kotfis K. 2020. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J. Clin. Med. 9 (6): 1917. doi: 10.3390/jcm9061917
Polak S.B., Van Gool I.C., Cohen D., von der Thüsen J.H., van Paassen J. 2020. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 33 (11): 2128-2138. doi: 10.1038/s41379-020-0603-3